IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): The use of An anticancer medicinal product

comprising an antitumor and leukocyte-protecting active ingredient and an antitumor-andleukocyte-protecting amount of a superoxide dismutase and glutathione reductase mimetic as
an antitumor and leukocyte-protecting active ingredient, for obtaining an anticancer

medicinal product.

Claim 2 (Currently Amended): The use as product claimed in claim 1, characterized in that wherein said mimetic is mangafodipir.

Claim 3 (Currently Amended): The use as claimed in either one of claims 1 and 2, eharacterized in that product as claimed in claim 1, wherein said mimetic is used in combination with an antitumor agent capable of inducing a reactive oxygen species production in cells.

Claim 4 (Currently Amended): The [[use]] <u>product</u> as claimed in claim 3, eharacterized in that <u>wherein</u> said antitumor agent is chosen from doxorubicin, mitomycin C, etoposide, platinum derivatives, tamoxifen, taxol, 5-fluorouracil, irinotecan, gemcitabine, endoxan, streptozotocin, bleomycin and vincristine.

Claim 5 (Original): A pharmaceutical composition comprising a superoxide dismutase and glutathione reductase mimemtic, combined with an antitumor agent chosen from oxaliplatin, 5-fluorouracil and taxol.

Claim 6 (Currently Amended): The pharmaceutical composition as claimed in claim 5, characterized in that wherein said mimetic is mangafodipir.